Food, Fungals, and Flexibility: Real-World Dosing of Revumenib

Caitlin Rausch, PharmD, BCOP, a leukemia pharmacist at MD Anderson Cancer Center with hands-on experience treating patients in the AUGMENT-101 trial, unpacks newly reported pharmacokinetic data for revumenib, the oral menin-KMT2A inhibitor approved for relapsed/refractory acute leukemia with a KMT2A rearrangement or a susceptible NPM1 mutation. You can find more expert insights at PharmacyTimes.com, where we provide pharmacy news, clinical insights, & continuing education to help pharmacists deliver drug expertise & accessible patient care. Original Interview: Visit Pharmacy Times: https://www.pharmacytimes.com/ Follow Pharmacy Times on social media! X: @Pharmacy_Times Facebook: Pharmacy Times LinkedIn: Pharmacy Times BlueSky: @PharmacyTimes.bsky.social TikTok: @pharmacytimes #pharmacy #pharma #pharmacist